Welcome to our dedicated page for Shattuck Labs news (Ticker: STTK), a resource for investors and traders seeking the latest updates and insights on Shattuck Labs stock.
Shattuck Labs, Inc. (STTK) is a clinical-stage biotechnology company developing innovative dual-function fusion proteins targeting cancer and autoimmune diseases. This page serves as the definitive source for official company announcements, research milestones, and financial updates.
Investors and industry professionals will find timely updates on STTK's clinical trials, regulatory developments, and strategic partnerships. The curated news collection includes press releases on pipeline advancements, collaborations with pharmaceutical leaders, and progress across its proprietary ARC® platform programs.
Key content categories include updates on lead candidates like SL-172154, financial reporting disclosures, and scientific presentations. All materials are sourced directly from company communications to ensure accuracy and compliance.
Bookmark this page for streamlined access to STTK's latest developments in bi-functional therapeutics. Check regularly for critical updates impacting the company's position in immuno-oncology and autoimmune treatment innovation.
Shattuck Labs reported promising initial clinical data for its bi-functional fusion proteins SL-172154 and SL-279252 in heavily pretreated cancer patients. The data, presented at the Society for the Immunotherapy of Cancer meeting, highlighted favorable safety profiles, dose-dependent immune activation, and evidence of anti-tumor activity. The company also disclosed a significant increase in collaboration revenue from $1.3 million in Q4 2020 to $30.1 million in Q4 2021. Shattuck's cash position stood at $268.8 million, sufficient to support operations into the second half of 2024.
Shattuck Labs, Inc. (NASDAQ: STTK) announced the acceptance of two posters for presentation at the American Association for Cancer Research (AACR) Annual Meeting, April 8-13, 2022, in New Orleans. The posters will feature preclinical data from their GADLEN™ and ARC® platforms, focusing on cancer treatment advancements. Dr. Anne Lai will present on bispecific gamma delta T cell engagers on April 12, while Dr. George Fromm and Kyung Jin Yoo will discuss LIGHT costimulation with TIGIT blockade on April 13. More details and poster access will be available on their website post-event.
Shattuck Labs, Inc. (NASDAQ: STTK), a clinical-stage biotechnology firm, announced participation in two virtual investor conferences in March 2022. The first conference is the 42nd Annual Cowen Healthcare Conference on March 9, featuring a panel discussion on ovarian cancer, presented by Chief Medical Officer Lini Pandite. The second is Oppenheimer's 32nd Annual Healthcare Conference on March 15, with a corporate presentation by Conor Richardson, Senior Director of Finance. Both presentations will be available via live webcast and archived for 90 days.
Shattuck Labs, a clinical-stage biotechnology company (NASDAQ: STTK), will participate in the 11th Annual SVB Leerink Global Healthcare Conference from February 14-18, 2022. CEO Taylor Schreiber will present on February 18 at 10:40 a.m. EST. The company focuses on developing bi-functional fusion proteins for treating cancer and autoimmune diseases, currently conducting three Phase 1 clinical trials, including its SL-172154 and SL-279252 programs. A live webcast of the presentation will be available on their website, with a replay accessible for 90 days.
Shattuck Labs, Inc. (NASDAQ: STTK), a clinical-stage biotechnology firm, announced its participation in two virtual investor conferences this January 2022. CEO Taylor Schreiber will present at the H.C. Wainwright BioConnect 2022 Conference on January 10 at 7:00 a.m. EST and the 40th Annual J.P. Morgan Healthcare Conference on January 13 at 11:15 a.m. EST. The company is advancing bi-functional fusion proteins targeting cancer and autoimmune diseases, with three ongoing Phase 1 clinical trials. Webcasts will be available live and archived for 90 days on their website.
Shattuck Labs, a clinical-stage biotechnology company (NASDAQ: STTK), is set to present at the TIGIT Therapies Digital Summit 2021 from December 7-9. CEO Taylor Schreiber will present on December 9 at 9:30 a.m. EST, discussing TIGIT blockade in refractory tumors. Shattuck is advancing bi-functional fusion proteins targeting cancer and autoimmune diseases, with three ongoing Phase 1 trials. The presentation will be available for download on the company's website and to registered participants of the summit.
Shattuck Labs announced promising Phase 1 trial data for SL-172154 targeting ovarian cancer and SL-279252 for solid tumors at the SITC annual meeting. Both trials show favorable safety profiles and evidence of immune activation. An open IND for SL-172154 in acute myeloid leukemia was also disclosed. However, Shattuck and Takeda terminated their collaboration agreement. The company's Q3 financial results reveal a net loss of $17.4 million, up from $11.8 million year-over-year, with cash reserves sufficient to fund operations into 2024.
Shattuck Labs (NASDAQ: STTK) reports promising initial data from its Phase 1 clinical trials for two compounds, SL-172154 and SL-279252, targeting advanced cancers. SL-172154 shows favorable safety, high CD47 target occupancy, and potential for use in treating acute myeloid leukemia and myelodysplastic syndromes. SL-279252 exhibited anti-tumor activity in heavily pretreated melanoma patients, including one confirmed partial response. The data will be showcased at the Society for Immunotherapy of Cancer's annual meeting and discussed in a conference call on November 12, 2021.
Shattuck Labs, Inc. (NASDAQ: STTK), a biotechnology company, will host a live webcast on November 12, 2021, at 8:00 a.m. ET, to present clinical data from ongoing Phase 1 trials. The event features CEO Taylor Schreiber along with other executives discussing their lead bi-functional fusion proteins. Highlights include data for SL-172154 in ovarian cancer and SL-279252 in solid tumors and lymphoma. The presentation will be accessible via conference call and archived online for 90 days.
Austin-based Shattuck Labs (STTK) is a clinical-stage biotechnology company focused on bi-functional fusion proteins for treating cancer and autoimmune diseases. They have three ongoing Phase 1 clinical trials and announced participation in four upcoming virtual investor conferences this November. Key presentations include the Berenberg US CEO Conference on November 10 and the Cowen IO Next Summit on November 15, featuring CEO Taylor Schreiber. A live webcast of these events will be available on their website, with replays archived for 90 days.
FAQ
What is the current stock price of Shattuck Labs (STTK)?
What is the market cap of Shattuck Labs (STTK)?
